MESO (Mesoblast) Short-Term Debt : $13.86 Mil (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Short-Term Debt?

Mesoblast's Short-Term Debt for the quarter that ended in Jun. 2024 was $13.86 Mil.

Mesoblast's quarterly Short-Term Debt declined from Dec. 2023 ($8.53 Mil) to Mar. 2024 ($0.00 Mil) but then increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($13.86 Mil).

Mesoblast's annual Short-Term Debt increased from Jun. 2022 ($5.02 Mil) to Jun. 2023 ($5.95 Mil) and increased from Jun. 2023 ($5.95 Mil) to Jun. 2024 ($13.86 Mil).

Mesoblast Short-Term Debt Historical Data

The historical data trend for Mesoblast's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Short-Term Debt Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Debt

Get a 7-Day Free Trial

32.46

53.20

5.02

5.95

13.86

Mesoblast Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	8.53	-	13.86	-

Mesoblast Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Mesoblast Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Mesoblast's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

MEOBF:USA LWB:Germany LWB:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.